June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
CD362+ stromal stem cells (SSCs) promote revascularisation of the retina in a paracrine manner
Author Affiliations & Notes
  • Vickie Hoi Ying Wong
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
  • Lynsey-Dawn Allen
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
  • Jasenka Guduric-Fuchs
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
  • Reinhold J Medina
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
  • Camilo Acuna Medina
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
  • Steve Elliman
    Orbsen Therapeutics, Galway, Ireland
  • Paul Loftus
    Orbsen Therapeutics, Galway, Ireland
  • Lisa O'Flynn
    Orbsen Therapeutics, Galway, Ireland
  • Alan W Stitt
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
  • Footnotes
    Commercial Relationships Vickie Wong, None; Lynsey-Dawn Allen, None; Jasenka Guduric-Fuchs, None; Reinhold Medina, None; Camilo Medina, None; Steve Elliman, Orbsen Therapeutics (E); Paul Loftus, Orbsen Therapeutics (E); Lisa O'Flynn, Orbsen Therapeutics (E); Alan Stitt, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1828. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Vickie Hoi Ying Wong, Lynsey-Dawn Allen, Jasenka Guduric-Fuchs, Reinhold J Medina, Camilo Acuna Medina, Steve Elliman, Paul Loftus, Lisa O'Flynn, Alan W Stitt; CD362+ stromal stem cells (SSCs) promote revascularisation of the retina in a paracrine manner. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1828.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Current therapies for ischaemic retinopathies, such as diabetic retinopathy and retinal vein occlusion, are limited and do not address the primary vascular insufficiency that underpins these conditions. As a novel therapeutic approach, we have assessed vasoreparative potential of a defined population of human bone marrow-derived SSCs (CD362+SSCs) in the ischaemic retina.

Methods: C57/Bl6 mice pups (postnatal day 7, P7) were subjected to an experimental model of oxygen-induced retinopathy by exposure to high oxygen (75% oxygen, 5 days). At P13 mice received a 1µl intravitreal injection in one eye containing Qdot nanocrystal labelled CD362+, CD362-, plastic adherent SSCs (PA-SSCs) or CD362+SSC-conditioned media (CM). Cell numbers delivered were low [1x103], medium [1x104] or high [1x105]. The contralateral eye was injected with vehicle (DMEM) as a control. Three days post-injection, retinal flatmounts were processed and stained with isolectin B4/streptavidin-AlexaFluor488, and imaged using confocal microscopy. Retinal vasculature was quantified using ImageJ software (avascular or neovascular area/total area,%). All data are shown as mean±SEM. Two-tailed paired t-test was used for statistical analysis.

Results: CD362+SSCs localised to the murine retina in a perivascular manner. Intravitreal delivery of CD362+SSCs showed a significantly reduced avascular area than control at medium (P=0.031, n=6) and high cell numbers (P=0.046, n=11). No difference was found for low dose (P=0.507, n=5). CD362-SSCs also promoted revascularisation at medium cell dose only (P=0.038, n=9). PA-SSCs did not have a significant effect on avascular areas for all doses (low: P=0.739, n=4; medium: P=0.085, n=8; high: P=0.741, n=12). This increased revascularisation may be a result of some CD362 cells associating with host vasculature. No difference was found in neovascularisation areas (P>0.050) for all groups. When treated with CD362+SSC-CM, both avascular (P=0.006, n=9) and pre-retinal neovascular areas (P=0.019) were significantly reduced.

Conclusions: As a novel, highly defined population of bone marrow-derived cells, CD362+SSCs associate closely with the host vasculature and promote revascularisation of the ischaemic retina via secretion of complex paracrine factors. These findings suggest that human CD362+SSCs may have utility for cell therapy to address retinal ischaemia.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×